Yann-Alexandre Vano, MD, explains some of the findings from the phase 2 BIONIKK trial which evaluated nivolumab and ipilimumab in metastatic renal cell carcinoma.
Yann-Alexandre Vano, MD, Georges-Pompidou European Hospital, Paris, France, explains some of the findings from the phase 2 BIONIKK trial (NCT02960906) which evaluated nivolumab (Opdivo) and ipilimumab (Yervoy) in metastatic renal cell carcinoma (RCC).
Vano explains some of the findings and demonstrates the feasibility of a prospective patient selection based on tumor molecular phenotype to determine what the most effective treatments for first-line RCC is when comparing nivolumab with or without ipilimumab and a VEGFR-tyrosine kinase inhibitor (TKI).
Transcription:
0:08 | The second part is treatment progression because we recorded the second-line treatment after progression. Nearly 67% of patients receive the second-line treatment and almost all 80% of these patients received the TKI, which is quite interesting to look at because most of these TKI’s are cabozantinib in 54% of the patients, which is the most effective TKI in the second-line or later. We see that the efficacy of the TKI seems to be higher plus nivolumab and ipilimumab in group 4 vs with nivolumab alone with a 33% objective response rate plus nivo/ipi in group 4, and an 11% response rate with nivo in group 4.
0:56 | So clearly there are some things that happened with nivolumab and ipilimumab with the TKI, particularly in group 4. In group 1, we had the same results. The median PFS was also consistent with a higher median PFS post nivo/ipi group for nearly 12 months vs 8 or 9 months in group 4. For group 2, the TKI plus TKI performed extremely well with more than 60% objective response rate, and the TKI plus nivolumab and ipilimumab group performed extremely well, also with a very high response rate and median PFS are nearly 12 months.
1:42 | These results suggest that the second-line is influenced or impacted by the first-line treatments and by the molecular group defined at the beginning. These are hypothesis generating data, but it demonstrates the feasibility of these kinds of biomarker driven trials and it opens a new way to think about new designs with biomarker-based clinical trials.
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Comparing Choices for IO/TKI Combinations in Advanced RCC
May 2nd 2024During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
Sustained Treatment-Free Survival in RCC Seen With Nivolumab and Ipilimumab
April 30th 2024Nivolumab monotherapy plus salvage nivolumab/ipilimumab demonstrated superior treatment-free survival rates among patients with advanced renal cell carcinoma, especially in patients with favorable risk profiles.
Read More
Roundtable Roundup April: Renal Cell Carcinoma
April 27th 2024In separate, live virtual events, Arnab Basu, MD, MPH, and Robert J. Motzer, MD, asked participants which therapy they would choose for a patient with clear cell renal cell carcinoma (RCC) and why they would make that choice.
Read More